SavedAdd your journal

Journals / Experimental Biomedical Research / 2021 / Cilt: 4 - Sayı: 2

Effect of vitamin D level and polypharmacy on the risk of falls in the elderly

Gamze DİLEK
Yalkın ÇALIK
KAĞAN ÖZKUK
Pages
81–88
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Medical therapies for the treatment of diseases in the elderly should have a rational basis, as this may reduce falls, particularly in the elderly population, that can have serious consequences, and may even lead to death.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To investigate the effects of polypharmacy and vitamin D levels on the risk of falls in the elderly.
📊
Key Findings & Data:Methods: The prospective study included 201 patients (F/M: 155/46) aged 65 years and older who presented with nonspecific musculoskeletal pain.
💡
Conclusion & Impact:Conclusion: Medical therapies for the treatment of diseases in the elderly should have a rational basis, as this may reduce falls, particularly in the elderly population, that can have serious consequences, and may even lead to death.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aim: To investigate the effects of polypharmacy and vitamin D levels on the risk of falls in the elderly. Methods: The prospective study included 201 patients (F/M: 155/46) aged 65 years and older who presented with nonspecific musculoskeletal pain. The demographic and laboratory data of the patients, as well as the results of a single leg stance test (SLST), a timed up and go (TUG) test and levels of vitamin D were recorded. Results: The percentage of patients with polypharmacy is 15.9 percent and 29.4 percent used no medications. The SLST score was the lowest and the TUG test score was significantly higher in the polypharmacy group (p 0.05). Conclusion: Medical therapies for the treatment of diseases in the elderly should have a rational basis, as this may reduce falls, particularly in the elderly population, that can have serious consequences, and may even lead to death.

🔖

Cite This Article

DİLEK, G., ÇALIK, Y., ÖZKUK, K. (2021). Effect of vitamin D level and polypharmacy on the risk of falls in the elderly. Experimental Biomedical Research, Cilt: 4 - Sayı: 2, 81–88. https://ajindex.com/articles/212420

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Wu TY, Chie WC, Yang RS, et al. Factors associated with falls among communitydwelling older people in Taiwan. Ann Acad Med Singap. 2013
  2. 42(7):320-27. [2]Moylan KC, Binder EF. Falls in older adults: risk assessment, management and prevention. Am J Med. 2007
  3. 120(6):493.e1- 6. [3]Richardson K, Bennett K, Kenny RA. Polypharmacy including falls riskincreasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age Ageing. 2015
  4. 44(1):90- 96. [4]Baranzini F, Diurni M, Ceccon F, et al. Fallrelated injuries in a nursing home setting: is polypharmacy a risk factor? BMC Health Serv Res. 2009
  5. Hammond T, Wilson A. Polypharmacy and falls in elderly: A literatüre review. Nurs Midwifery Stud. 2013
  6. 2(2):171-75. [6]Kalyani RR, Stein B, Vliyil R, et al. Vitamin D treatment for the prevention of falls in older adults: Systematic review and metaanalysis. J Am Geriatr Soc. 2010
  7. 58(7):1299-310. [7]Ziere G, Dieleman JP, Hofman A, et al. Polypharmacy and falls in the middle age and elderly population. B J Clin Pharmacol. 2005
  8. 61(2):218-23. [8]Ambrose AF, Paul G, Hausdorff JM. Risk factors for falls among older adults: A review of the literatüre. Maturitas. 2013
  9. 75(1):51-61. [9]Kojima T, Akishita M, Nakamura T, el al. Association of the polypharmacy with fall risk among geriatric outpatients. Geriatr Gerontol Int. 2011
  10. 11(4):438-44. [10]Zia A, Kamaruzzzaman SB, Tan MP. The consumption of two or more fallriskincreasing drugs rather than polypharmacy is associated with falls. Geriatr Gerontol Int. 2017
  11. 17(3):436-70. [11]Skalska A, Gałaś A, Grodzicki T. 25- hydroxyvitamin D and physical and cognitive performance in older people with chronic conditions. Pol Arch Med Wewn. 2012
  12. 122(4):162-69. [12]Pan HH, Li CY, Chen TJ, et al. Association of polypharmacy with fall-related fractures in older Taiwanese people: age- and genderspecific analyses. BMJ Open. 2014
  13. 4(3):e004428. [13]Halfon M, Phan O, Teta D. Vitamin D: a review on its effects on muscle strength, the risk of fall, and frailty. Biomed Res Int. 2015
  14. 953241. [14]Romagnoli E, Pepe J, Piemonte S, et al. Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. Eur J Endocrinol. 2013
  15. 169(4):59-69. [15]Fried TR, O’leary J, Towle V, et al. Health outcomes associated with polypharmacy in Community Dwelling older adults: A systematic review J Am Geriatr Soc. 2014
  16. 62(12):2261-72. [16]Balaban Ö,